Modification of mRNA Poly(A) Tails to Augment Expression
Therapeutic mRNA has recently emerged as a new platform for vaccine development. Despite recent advances in therapeutic mRNA engineering, the platform remains limited in its utility by its relatively short lifetime. Chemical modification of nucleotides is a promising method to increase nucleic acid stability, and is frequently used in engineered anti-sense oligos (ASOs). Here we describe a strategy to augment therapeutic mRNA stability by engineering poly(A) tails with enhanced nuclease resistance.